Table 4.
Examples of mAb-functionalized nanoparticles for targeted drug delivery.
| Carrier | Drug | Antibody | Target | Tumor Model | Ref. |
|---|---|---|---|---|---|
| PEG-nanomicelle | Taxol | α-nucleosome | Nucleosome | Lewis lung carcinoma (in vitro and in vivo) |
[51] |
| Liposome | Paclitaxel + salinomycin | Clone 2C5 | Nucleolin | Breast cancer (in vitro) |
[52] |
| Nanorod | Paclitaxel | Trastuzumab | HER2 | Breast cancer (in vitro) |
[55] |
| Gold nanorod/ PLGA-PEG nanoparticle |
Paclitaxel | Trastuzumab | HER2 | Breast cancer (in vitro) |
[56] |
| Chitosan/PLGA nanoparticle |
Doxorubicin | Trastuzumab | HER2 | Breast cancer (in vitro) |
[57] |
| Fucoidan/chitosan nanoparticle |
Gemcitabine | Clone 7H3L20 | HER2 | Breast cancer (in vitro and in vivo) |
[58] |
| Gold nanoparticle | Cetuximab | EGFR | Colorectal cancer (in vitro) |
[59] | |
| PLGA-PEG nanoparticle |
5-FU | α- EGFR | EGFR | Colorectal cancer (in vitro) |
[60] |
| Chitosan/PEG nanocapsule |
Docetaxel | Chi-Tn | Tn-antigen | Lung cancer (in vitro) |
[61] |
| Lipid nanocapsule | Paclitaxel | α-CD44 | CD44 | Pancreatic cancer (in vitro and in vivo) |
[62] |
| Solid lipid nanoparticle |
γ-secretase inhibitor | α-DR5 | DR5 | Breast cancer (in vitro and in vivo) |
[64] |
| Halloysite nanotube |
Docetaxel+ gold | Clone 2D8-E3 | Sortilin | Ovarian carcinoma (in vitro) |
[66] |
| PEG-polymer/ prodrug |
Camptothecin | α-CD147 | CD147 | Liver cancer (in vitro) |
[67] |